The Virtual Cancer Center Director Award (VCCDA) mechanism is a unique, interactive virtual Cancer center (VCC) focused on bringing together two established investigators (Director and Deputy Director) and up to nine early career investigators (Scholars) to interrogate the commonalities of Cancer. Candidates for Scholars will apply to a separate funding opportunity (W81XWH-20-PRCRP-CDA). The Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with the Scholars' Career Guides, assess the progress of the Scholars, promote the cross pollination of different Cancer disciplines, and facilitate communication and collaboration amongst all of the VCC members. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will provide intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge center to lead Cancer research to a new frontier. It is the intention that through the VCC, collaborations will foster new growth in different Cancers and spur an integrated Cancer center to ensure the research advancements across different Cancers.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult Cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established Cancers in adults or to prevent Cancers before they occur.
The purpose of this FOA is to establish a Cancer Immunotherapy Consortium (CIC) composed of organ site-specific Cancer Immunotherapy Research Projects as a component of the Immuno-Oncology Translation Network (IOTN). The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-Cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult Cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established Cancers in adults or to prevent Cancers before they occur.
The purpose of this specific FOA is to establish Cancer Immunoprevention Research Projects that will function as components of a Cancer Immunotherapy Consortium (CIC), which will also include Cancer Immunotherapy Research Projects. The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression, and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications.
The Pancreatic Cancer Action Network-AACR Innovative Grants represent a joint effort to promote and support innovative pancreatic Cancer research. They aim to spur creative and cutting-edge ideas and approaches in pancreatic Cancer research, including those successful in other areas of Cancer that have justifiable promise for pancreatic Cancer. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic Cancer.
These grants are available to full time, independent junior and senior investigators, including those with experience in other areas of Cancer or biomedical/health science research who have promising ideas and approaches that can be applied to pancreatic Cancer research.
The grants provide $200,000 over two years ($100,000 per year) for direct and indirect expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators (grant recipient/collaborator salaries limited to 20 percent of the total grant), postdoctoral or clinical research fellows, graduate students and/or research assistants, research/laboratory supplies, equipment and publication charges for manuscripts that pertain directly to the funded project.
It is anticipated that multiple Innovative Grants will be funded.
The Pancreatic Cancer Action Network-AACR Innovative Grants represent a joint effort to promote and support innovative pancreatic Cancer research. They aim to spur creative and cutting-edge ideas and approaches in pancreatic Cancer research, including those successful in other areas of Cancer that have justifiable promise for pancreatic Cancer. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic Cancer.
These grants are available to full time, independent junior and senior investigators, including those with experience in other areas of Cancer or biomedical/health science research who have promising ideas and approaches that can be applied to pancreatic Cancer research.
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention intervention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities.
The National Cancer Institute (NCI), through its Center for Global Health (CGH), seeks to promote Cancer prevention and control (CPC) research in low- and middle-income countries (LMICs) through collaborations and research partnerships between the NCI-designated Cancer centers and partner institutions in LMICs. Through this funding opportunity announcement (FOA), the NCI will provide administrative supplement awards to currently-funded P30 NCI-designated Cancer center grantees to support pilot research plans that focus on Cancer prevention and control. These supplements are designed to stimulate and strengthen CPC twinning programs between researchers at the NCI-designated Cancer centers and institutions in LMICs. It is anticipated that outcomes of this supplement will include collaborative research grants between investigators at the NCI-designated Cancer centers and LMIC institutions.
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies for the molecular or cellular analysis of cancer. Emerging technologies with significant transformative potential that have not yet been explored in a cancer-relevant use may also be considered. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of cancer-relevant use intended in the application and requires significant modification for the proposed application to establish feasibility. The emphasis of this FOA is on molecular analysis technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated program project (P01) grants. Proposed program projects may address any of the broad areas of Cancer research, including (but not limited to) Cancer biology, Cancer prevention, Cancer diagnosis, Cancer treatment, and Cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each Program Project application must consist of at least three projects. The projects must share a common central theme, focus, and/or overall objective.
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide-ranging areas. cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental proposal is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging areas. cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental request is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of Cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of Cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with Cancer development. This initiative should include demonstration projects that will show how Cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary Cancers, with the goal of improving prevention and detection.
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of Cancer research, including (but not limited to) Cancer biology, Cancer prevention, Cancer diagnosis, Cancer treatment, and Cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established Cancers in adults or to prevent Cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult Cancers. The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-Cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as
(1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies,
(2) the development and testing of new methodologies and models, and
(3) secondary data analyses
This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of Cancer research, including (but not limited to) Cancer biology, Cancer prevention, Cancer diagnosis, Cancer treatment, and Cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative (https://www.Cancer.gov/research/key-initiatives/moonshot-Cancer-initiative) that is intended to accelerate Cancer research. Through this FOA, the National Cancer Institute (NCI) invites the submission of applications requesting support for projects that will be conducted to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve Cancer risk communication between patients with an inherited susceptibility to Cancer (and their families) and providers so that the affected individuals can make informed clinical risk management decisions. This FOA will allow interventional clinical studies that meet NIH's definition of a clinical trial (NIH's Definition of a Clinical Trial). Specifically, this FOA targets Blue Ribbon Panel Recommendation G.
The Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research was established to recognize the outstanding achievement of a junior faculty-level scientist working in the field of Cancer prevention, and support his or her novel and innovative research that, if successful, will have the potential for high impact in the Cancer prevention field. The goal of the grant program is to encourage junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to pursue novel, high-risk, high-reward Cancer prevention research. Travel support is included to help foster interactions and collaborations among Cancer scientists studying various aspects of Cancer biology and to disseminate scientific knowledge about Cancer prevention research within the field.
